Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Similar articles for PubMed (Select 21333567)

1.

Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.

Thamm DH, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, Hermine O, Dubreuil P.

Vet J. 2012 Jan;191(1):131-4. doi: 10.1016/j.tvjl.2011.01.001. Epub 2011 Feb 17.

PMID:
21333567
2.

Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.

Asada H, Tomiyasu H, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H.

J Vet Med Sci. 2015 Jul 1;77(6):677-84. doi: 10.1292/jvms.14-0415. Epub 2015 Feb 21.

3.

Identification of anti-proliferative kinase inhibitors as potential therapeutic agents to treat canine osteosarcoma.

Mauchle U, Selvarajah GT, Mol JA, Kirpensteijn J, Verheije MH.

Vet J. 2014 Aug 11. pii: S1090-0233(14)00327-X. doi: 10.1016/j.tvjl.2014.08.006. [Epub ahead of print]

PMID:
25190293
4.

Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.

Turek M, Gogal R Jr, Saba C, Vandenplas ML, Hill J, Feldhausser B, Lawrence J.

Res Vet Sci. 2014 Apr;96(2):304-7. doi: 10.1016/j.rvsc.2014.02.001. Epub 2014 Feb 11.

PMID:
24602916
5.

Masitinib (AB1010), from canine tumor model to human clinical development: where we are?

Marech I, Patruno R, Zizzo N, Gadaleta C, Introna M, Zito AF, Gadaleta CD, Ranieri G.

Crit Rev Oncol Hematol. 2014 Jul;91(1):98-111. doi: 10.1016/j.critrevonc.2013.12.011. Epub 2013 Dec 17. Review.

PMID:
24405856
6.

Masitinib-associated minimal change disease with acute tubular necrosis resulting in acute kidney injury in a dog.

Brown MR, Cianciolo RE, Nabity MB, Brown CA, Clubb FJ, Lees GE.

J Vet Intern Med. 2013 Nov-Dec;27(6):1622-6. doi: 10.1111/jvim.12189. Epub 2013 Sep 10. No abstract available.

PMID:
24020652
7.

Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.

Smrkovski OA, Essick L, Rohrbach BW, Legendre AM.

Vet Comp Oncol. 2013 Jul 12. doi: 10.1111/vco.12053. [Epub ahead of print]

PMID:
23845124
8.

Influence of different cell storage/culture conditions on spontaneous proliferation and level of tyrosine kinase receptor inhibition in two feline injection-site sarcoma cell lines.

Feldhaeusser BR, Turek M, Lawrence J, Cornell K, Gogal RM Jr.

J Immunoassay Immunochem. 2013;34(3):266-82. doi: 10.1080/15321819.2012.722577.

PMID:
23656247
9.

Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.

Fahey CE, Milner RJ, Kow K, Bacon NJ, Salute ME.

Anticancer Drugs. 2013 Jun;24(5):519-26. doi: 10.1097/CAD.0b013e32836002ba.

PMID:
23466652
10.

Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.

Ito K, Kuroki S, Kobayashi M, Ono K, Washizu T, Bonkobara M.

Vet J. 2013 Jun;196(3):536-40. doi: 10.1016/j.tvjl.2012.12.016. Epub 2013 Jan 29.

PMID:
23369384
11.

Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.

Zandvliet M, Teske E, Chapuis T, Fink-Gremmels J, Schrickx JA.

J Vet Pharmacol Ther. 2013 Dec;36(6):583-7. doi: 10.1111/jvp.12039. Epub 2013 Jan 31.

PMID:
23363222
12.

Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.

Xiao Z, Ding N, Xiao G, Wang S, Wu Y, Tang L.

Anat Rec (Hoboken). 2012 Dec;295(12):2122-8. doi: 10.1002/ar.22552. Epub 2012 Aug 21.

13.

Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines.

de Brito Galvao JF, Kisseberth WC, Murahari S, Sutayatram S, Chew DJ, Inpanbutr N.

Am J Vet Res. 2012 Aug;73(8):1262-72. doi: 10.2460/ajvr.73.8.1262.

PMID:
22849687
14.

Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.

Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Gaivão I, Cardoso ML, Colaço A, Santos L, Oliveira P.

J Toxicol Environ Health A. 2012;75(13-15):788-99. doi: 10.1080/15287394.2012.690325.

PMID:
22788366
15.

Novel indeno[1,2-b]indoloquinones as inhibitors of the human protein kinase CK2 with antiproliferative activity towards a broad panel of cancer cell lines.

Hundsdörfer C, Hemmerling HJ, Hamberger J, Le Borgne M, Bednarski P, Götz C, Totzke F, Jose J.

Biochem Biophys Res Commun. 2012 Jul 20;424(1):71-5. doi: 10.1016/j.bbrc.2012.06.068. Epub 2012 Jun 21.

PMID:
22728884
16.

In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.

Lyles SE, Milner RJ, Kow K, Salute ME.

Vet Comp Oncol. 2012 Sep;10(3):223-35. doi: 10.1111/j.1476-5829.2012.00335.x. Epub 2012 May 18.

PMID:
22594682
17.

Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (sp) transcription factors, and sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells.

Wilson H, Chadalapaka G, Jutooru I, Sheppard S, Pfent C, Safe S.

J Vet Intern Med. 2012 Jul-Aug;26(4):977-86. doi: 10.1111/j.1939-1676.2012.00931.x. Epub 2012 Apr 27.

PMID:
22536857
18.

Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-κB pathway.

Liang C, Li H, Shen C, Lai J, Shi Z, Liu B, Tao HM.

Anticancer Agents Med Chem. 2012 Jun;12(5):554-63.

PMID:
22263786
19.

Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.

Lawrence J, Saba C, Gogal R Jr, Lamberth O, Vandenplas ML, Hurley DJ, Dubreuil P, Hermine O, Dobbin K, Turek M.

Vet Comp Oncol. 2012 Jun;10(2):143-54. doi: 10.1111/j.1476-5829.2011.00291.x. Epub 2011 Aug 25.

PMID:
22236016
20.

Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines.

Guo Y, Xu X, Qi W, Xie C, Wang G, Zhang A, Ge Y.

Mol Med Rep. 2012 Mar;5(3):734-8. doi: 10.3892/mmr.2011.738. Epub 2011 Dec 23.

PMID:
22200913
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk